NICE approval for ustekinumab

The monoclonal antibody ustekinumab (Stelara) has been endorsed by NICE for use in patients with severe plaque psoriasis who have not responded to, or have an intolerance or contraindication to, standard systemic therapies.

Ustekinumab (Stelara) is thought to interrupt signalling and cytokine cascades relevant to psoriasis pathology.
Ustekinumab (Stelara) is thought to interrupt signalling and cytokine cascades relevant to psoriasis pathology.

Ustekinumab, which inhibits the activation of immune cells by interleukins 12 and 23, is recommended for adults with a psoriasis area severity index (PASI) score of 10 or more and a dermatology life quality index (DLQI) score greater than 10.

NICE's approval is contingent on Stelara's manufacturer, Janssen-Cilag, providing the 90mg dose-needed in people who weigh more than 100kg-at the same total cost as a single 45mg vial.

Treatment with ustekinumab should be stopped if an adequate response is not achieved by 16 weeks. An adequate response is defined as either a 75% reduction in PASI score, or a 50% reduction in PASI score accompanied by a 5-point reduction in DLQI score.

Physicians may need to adjust the DLQI score if the patient has any disabilities or communication difficulties that could affect the assessment.

View Stelara drug record

NICE guidance on ustekinumab

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more